CA2107669C - Preparation for treating wounds and hemorrhoides - Google Patents

Preparation for treating wounds and hemorrhoides Download PDF

Info

Publication number
CA2107669C
CA2107669C CA002107669A CA2107669A CA2107669C CA 2107669 C CA2107669 C CA 2107669C CA 002107669 A CA002107669 A CA 002107669A CA 2107669 A CA2107669 A CA 2107669A CA 2107669 C CA2107669 C CA 2107669C
Authority
CA
Canada
Prior art keywords
beraprost
preparation
salts
active ingredient
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002107669A
Other languages
English (en)
French (fr)
Other versions
CA2107669A1 (en
Inventor
Makoto Okumura
Toshiaki Okuda
Tsutomu Nakamura
Motoyuki Yajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Kaken Pharmaceutical Co Ltd
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Toray Industries Inc filed Critical Kaken Pharmaceutical Co Ltd
Publication of CA2107669A1 publication Critical patent/CA2107669A1/en
Application granted granted Critical
Publication of CA2107669C publication Critical patent/CA2107669C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
CA002107669A 1992-02-07 1993-02-05 Preparation for treating wounds and hemorrhoides Expired - Fee Related CA2107669C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2280892 1992-02-07
JPH4-22808 1992-02-07
JP18986792 1992-06-24
JPH4-189867 1992-06-24
PCT/JP1993/000151 WO1993015739A1 (fr) 1992-02-07 1993-02-05 Remede destine aux blessures ou aux hemorroides

Publications (2)

Publication Number Publication Date
CA2107669A1 CA2107669A1 (en) 1993-08-08
CA2107669C true CA2107669C (en) 2004-06-01

Family

ID=26360087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107669A Expired - Fee Related CA2107669C (en) 1992-02-07 1993-02-05 Preparation for treating wounds and hemorrhoides

Country Status (8)

Country Link
US (3) US5403867A (Sortimente)
EP (1) EP0583482B1 (Sortimente)
JP (1) JP3209427B2 (Sortimente)
AT (1) ATE188119T1 (Sortimente)
CA (1) CA2107669C (Sortimente)
DE (1) DE69327432T2 (Sortimente)
TW (1) TW234691B (Sortimente)
WO (1) WO1993015739A1 (Sortimente)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
EP0583482B1 (en) * 1992-02-07 1999-12-29 Kaken Pharmaceutical Co., Ltd. Remedy for wound or hemorrhoid
AU696167B2 (en) * 1993-10-29 1998-09-03 Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
US5965611A (en) * 1994-06-02 1999-10-12 Teigin Limited Pharmaceutical composition for treating peripheral circulation disorders
AU713461B2 (en) * 1994-11-17 1999-12-02 Toray Industries, Inc. Preparation for percutaneous absorption
AU4732096A (en) * 1995-02-27 1996-09-18 Toray Industries, Inc. Remedy for pulmonary heart
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
WO2004014394A1 (ja) * 2002-08-09 2004-02-19 Taisho Pharmaceutical Co.,Ltd. 止痒剤
US20050009918A1 (en) 2003-04-02 2005-01-13 Nexmed (Holdings) Inc. Prostaglandin compositions and methods for the treatment of vasospasm
JP4157889B2 (ja) * 2003-06-25 2008-10-01 有限会社 循環器研究所 性交機能改善用外用製剤
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
BR112013025744A2 (pt) 2011-04-07 2016-08-16 Nexmed Holdings Inc composicões para tratamento da doença de raynaud
WO2014164886A1 (en) * 2013-03-13 2014-10-09 Allergan, Inc. Prostanoid receptor agonist compounds and their use
EP3484478B1 (en) 2016-07-15 2025-11-05 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
BR112021024073A2 (pt) 2019-05-31 2022-04-26 Viracta Subsidiary Inc Métodos de tratamento de cânceres associados a um vírus com inibidores de histona desacetilase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4025645A (en) * 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5391110A (en) * 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
EP0044711B1 (en) * 1980-07-22 1984-03-14 Ono Pharmaceutical Co., Ltd. 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof
DE3631169A1 (de) * 1986-09-11 1988-03-24 Schering Ag Prostacyclinderivate enthaltende mittel fuer die topische anwendung
WO1989003387A1 (fr) * 1987-10-16 1989-04-20 Toray Industries, Inc. DERIVES DE 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE-PGI2, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
JPH0311017A (ja) * 1989-06-06 1991-01-18 Green Cross Corp:The プロスタグランジンｅ↓１含有薬剤組成物
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
EP0583482B1 (en) * 1992-02-07 1999-12-29 Kaken Pharmaceutical Co., Ltd. Remedy for wound or hemorrhoid
CN1084190C (zh) * 1993-02-03 2002-05-08 帝人株式会社 含有前列环素作为活性成分的外用皮肤治疗剂组合物

Also Published As

Publication number Publication date
CA2107669A1 (en) 1993-08-08
US5403867A (en) 1995-04-04
ATE188119T1 (de) 2000-01-15
EP0583482A4 (en) 1995-05-03
US5852050A (en) 1998-12-22
DE69327432D1 (de) 2000-02-03
DE69327432T2 (de) 2000-05-18
TW234691B (Sortimente) 1994-11-21
WO1993015739A1 (fr) 1993-08-19
JP3209427B2 (ja) 2001-09-17
EP0583482B1 (en) 1999-12-29
EP0583482A1 (en) 1994-02-23
US5679707A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
CA2107669C (en) Preparation for treating wounds and hemorrhoides
JPWO1993015739A1 (ja) 創傷または痔疾治療剤
US5476664A (en) Treatment of warts using anthralins and occlusion
EP0980245B1 (en) Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction
CN115300508A (zh) 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
WO2007123867A2 (en) Stable solutions of prostaglandin and uses of same
US5489576A (en) Therapeutic agent for hemorrhoidal diseases
WO2005077364A1 (ja) ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
JP2003527430A (ja) １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
Hoeger et al. Acute multifocal skin necrosis: synergism between invasive streptococcal infection and cocaine-induced tissue ischaemia?
JP2025506988A (ja) 外用トラネキサム酸組成物及びその使用方法
WO2022218136A1 (zh) 腺嘌呤作为制备治疗糖尿病溃疡药物的应用
US4400378A (en) Pharmaceutical composition for the treatment of glaucoma
KR0174763B1 (ko) 창상 또는 치질 치료제
Hyde et al. Intrathecal morphine in a parturient with cystic fibrosis
US20240415794A1 (en) Topical tranexamic acid compositions and methods of use thereof
KR20050102663A (ko) 치질환 치료제
Rath et al. Preoperative cervical priming by intracervical application of a new sulprostone gel
Perry et al. Uterine trauma associated with midtrimester abortion induced by intra-amniotic prostaglandin F2α with and without concomitant use of oxytocin
Siddall-allum et al. Treatment of secondary postpartum haemorrhage with intramyometrial prostaglandin F2α
Ranjan et al. Evaluation of sulprostone for second trimester abortions and its effects on liver and kidney functions
JP4744143B2 (ja) メトロニダゾールの使用方法
Raman et al. Intrarectal gemeprost in the treatment of intractable postpartum haemorrhage due to uterine atony
CA2447883A1 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
Ledward et al. Stimulating uterine activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed